Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Viatris Inc (VTRS) Price & Performance

Roundhill Innov-100 0DTE Covered Call Strat ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Roundhill Innov-100 0DTE Covered Call Strat ETF vs Viatris Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.65, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Viatris Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.

QDTEVTRS
Sector
Income / Options OverlayHealth
52-Week High
$36.60$17.86
52-Week Low
$26.85$9.49
Market Cap
$19.09B
Enterprise Value
$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE trades at $28.86 with minimal daily movement (+0.07%). The ETF shows bearish technical signals with selling pressure outweighing buying signals 12-4. Recent news highlights concerns about the fund's sustainability as volatility declines and distributions are funded by return of capital, causing NAV erosion. The fund's 0.97% expense ratio consumes significant portions of its weekly payouts.

The outlook remains cautious given structural concerns about the fund's distribution model. While weekly income appeals to investors, the erosion of net asset value and dependence on return of capital present significant risks. Analyst sentiment has turned negative with recent downgrades citing underperformance in bull markets and unsustainable yield mechanics.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS